James J. Peters VAMC, Bronx, Department of Neurology, Mount Sinai School of Medicine, New York City, NY, US.
Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Munich, Germany, DE.
Tremor Other Hyperkinet Mov (N Y). 2021 Jan 11;11:1. doi: 10.5334/tohm.583.
The term "neuroacanthocytosis" (NA) is used for a spectrum of neurological disorders in which there are thorny red blood cells. While NA historically referred to disorders of lipoprotein absorption, we have promoted it as an overarching term for a group of basal ganglia disorders, with specific reference to two diseases that we defined as "core" NA syndromes. "Neuroacanthocytosis" has also been used to refer to a specific, now genetically-defined disease, otherwise known as "chorea-acanthocytosis". These various usages have resulted in diagnostic confusion, and in a number of cases have quite likely prevented the pursuance of precise, molecular, diagnosis. Disease nomenclature is an ever-evolving field, especially in the current era of expanding genetics, and naming proposals are often far from ideal. We, however, suggest that the term "neuroacanthocytosis" should no longer be generally used and if so, only with appropriate understanding of its limitations. Further, we propose that chorea-acanthocytosis be renamed as " disease" in accordance with its genetic etiology.
“神经棘红细胞增多症”(NA)一词用于一系列存在棘状红细胞的神经紊乱疾病。虽然 NA 历史上是指脂蛋白吸收障碍,但我们将其作为一类基底节疾病的统称,并特别提到我们定义为“核心”NA 综合征的两种疾病。“神经棘红细胞增多症”也曾用于指代一种特定的、现已明确基因的疾病,也称为“舞蹈棘红细胞增多症”。这些不同的用法导致了诊断上的混乱,在许多情况下,很可能阻碍了精确的分子诊断。疾病命名是一个不断发展的领域,尤其是在当前遗传学不断扩展的时代,命名建议往往远非理想。然而,我们建议不再普遍使用“神经棘红细胞增多症”一词,如果使用,也应适当了解其局限性。此外,我们建议根据其遗传病因将舞蹈棘红细胞增多症重新命名为“疾病”。